Stephen Hiscox, PhD

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, United Kingdom

I am currently Senior Lecturer in Cancer Biology within the School of Pharmacy and Pharmaceutical Sciences, Cardiff University, UK. I have a long-standing interest in cancer invasion and metastasis particularly in the context of drug resistance in a broad range of tumour types. My early translational work at the School of Medicine in Cardiff focused on understanding the role of c-Met signalling in GI cancers and my subsequent lab in the School of Pharmacy was one of the first to identify a role for Src family kinases in the acquired drug resistant phenotype in breast cancer.

The long term goal of our laboratory is to better understanding of the cellular and molecular pathways underlying metastasis in order to identify prognostic and predictive biomarkers and identify novel therapeutic targets to both prevent the occurrence of, and treat patients with, metastatic cancers. As such, my research group is actively engaged in three themes of multidisciplinary, cancer-focused research:
• Exploring the role of non-receptor tyrosine kinases as mediators of drug response and resistance and understanding their value as therapeutic targets.
• Investigating the complex interplay within the tumour microenvironment, exploring how tumour cells interact with, and are influenced by, fibroblasts and bone cells and how these interactions can support metastases.
• Identifying molecular determinants of adverse response to targeted therapies and determining their potential for (i) use as predictive biomarkers for cancer patients and (ii) therapeutic exploitation.